CVS Health completed its $8 billion acquisition of Signify Health. The combined company is expected to deliver a superior healthcare experience and drive improved health outcomes. (Nasdaq)
Carl Icahn said Illumina should bring back its former CEO “immediately.” The activist investor’s remarks are the latest in a brewing proxy fight with Illumina over the company’s $7.1 billion acquisition of cancer test developer Grail in 2021. (The Wall Street Journal)
Public health experts talked about what it means for the COVID-19 pandemic to end and how these changes will impact consumers and their families. On May 11, the United States will end the public health emergency declaration over COVID-19. (The A1)
The head of the U.K.’s biggest pharmaceutical lobby group has warned that CEOs have a poor view of Britain. Britain’s ambition to become a “science superpower” will fail unless the government reverses the country’s reputation as a poor place to invest, according to the country’s pharma lobby boss. (Bloomberg)
Bluebird Bio said it expects a delay on its sickle cell drug application with the Food and Drug Administration. The company may be able to file the application in a few weeks, depending on when the FDA provides feedback about Bluebird’s drug manufacturing process. (The Boston Globe)
